Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease

BACKGROUND: Combination therapy with thiopurines and anti-tumor necrosis factor (TNF) is superior to monotherapy in Crohn’s disease (CD) and ulcerative colitis (UC). The optimal dose of thiopurines in combination therapy remains unclear. We investigated the impact of thiopurine dose in combination t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nawaz, Ahmad, Glick, Laura R., Chaar, Abdelkader, Li, Darrick K., Gaidos, Jill K.J., Proctor, Deborah D., Al-Bawardy, Badr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756033/
https://www.ncbi.nlm.nih.gov/pubmed/36593807
http://dx.doi.org/10.20524/aog.2022.0766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756033/
https://www.ncbi.nlm.nih.gov/pubmed/36593807
http://dx.doi.org/10.20524/aog.2022.0766

Ejemplares similares